Policies, codes and standards
Codes of conduct
GSK Code of Conduct
- Our Code of Conduct
- Code of Practice for Promotion and Scientific Engagement (prescription medicines)
Anti-Bribery and Corruption (ABAC) Programme
The Anti-Bribery and Corruption (ABAC) Programme is part of GSK’s response to the threat and risk of bribery and corruption. The programme includes the ABAC Handbook, which has been designed to assist internal and external parties understand corruption risk and identify people’s responsibilities to actively combat both real and perceived corruption.
Anti-Bribery and Corruption Programme Third Party Guidelines
Third Party Guidelines are provided to all third parties that GSK engages with in order to make them aware of our anti-bribery and corruption policies and what we expect from them as our business partners
GSK access and developing countries
- Developing world vaccine production technology transfer
- IP and access to medicines in developing countries
- Technology transfer, capacity building and developing countries
- Non-communicable diseases and the developing world
- Universal healthcare coverage
- Civil society organisations and vaccine procurement
- Working together for the health of mothers and children
- The Sustainable Development Goals
GSK and research & development
- Clinical trials in the developing world
- Combating antimicrobial resistance
- Cloning technologies and stem cell research
- The convention on biological diversity
- Public disclosure of clinical research
- The care, welfare and treatment of animals
- The role of transgenic animals in biomedical research
- Use of Non-human Primates (NHPs) in the Discovery and Development of Medicines and Vaccines
GSK and intellectual property
- Incremental innovation
- Compulsory licences
- A disclosure requirement in patent applications
- Regulatory data protection
GSK and the environment
- Hazardous chemical management
- Genetically modified micro-organisms and Environment, Health and Safety (EHS)
- The EU REACH regulation
- Ozone depletion and metered-dose inhalers for asthma
- Pharmaceuticals in environment
- The impact of climate change on health
- Climate Change and GSK’s Operations
- Water stewardship
- Deforestation-free resourcing
GSK and public health
- Counterfeiting of healthcare products
- Paediatric medicines
- Tiered pricing & vaccines
- Pandemic preparedness
- Information to patients about prescription medicines
- Engagement with patient organisations
- Compassionate Use
GSK and business integrity
GlaxoSmithKline plc - Specialised Disclosure Report
- GlaxoSmithKline plc - 2015 Form SD Conflict Minerals Disclosure
- GlaxoSmithKline plc - 2014 Form SD Conflict Minerals Disclosure
- GlaxoSmithKline plc - 2013 Form SD Conflict Minerals Disclosure
GlaxoSmithKline plc and GlaxoSmithKline Capital plc Euro Medium Term Note Programme
- GlaxoSmithKline Euro Medium Term Note Programme – Prospectus Document 2016
- GlaxoSmithKline Euro Medium Term Note Programme – Prospectus Document 2015
- GlaxoSmithKline Euro Medium Term Note Programme – Prospectus Document 2014
- GlaxoSmithKline Euro Medium Term Note Programme – Prospectus Document 2013
- GlaxoSmithKline Euro Medium Term Note Programme – Registration Document
- GlaxoSmithKline Euro Medium Term Note Programme – Prospectus Document
- GlaxoSmithKline Euro Medium Term Note Programme - Supplementary Prospectus Document
GlaxoSmithKline Capital plc Annual Reports
- 2016 Half Year Results and Interim Management Report GlaxoSmithKline Capital plc
- 2015 Annual Report GlaxoSmithKline Capital plc
- 2015 Half Year Results and Interim Management Report GlaxoSmithKline Capital plc
- 2014 Annual Report GlaxoSmithKline Capital plc
- 2014 Half Year Results and Interim Management Report GlaxoSmithKline Capital plc
- 2013 Annual Report GlaxoSmithKline Capital plc
- 2013 Half Year Results and Interim Management Report GlaxoSmithKline Capital plc
- 2012 Annual Report GlaxoSmithKline Capital plc
- 2012 Half Year Results and Interim Management Report GlaxoSmithKline Capital plc
- 2011 Annual Report GlaxoSmithKline Capital plc
- 2011 Half Year Results and Interim Management Report GlaxoSmithKline Capital plc
- 2010 Annual Report GlaxoSmithKline Capital plc
- 2009 Annual Report GlaxoSmithKline Capital plc
- 2008 Annual Report GlaxoSmithKline Capital plc
UK Pension Schemes Statements of Investment Principles (SIP)
The links below will allow you to download the Statements of Investment Principles for the main UK pension schemes.
The contents of these documents are set out under UK law and cover the investment policies of the schemes in the following broad areas: Risk Measurement and Management, Implementation and Governance. The documents also provide details of the asset allocation of the investments.
The Statements have been agreed by the Trustee Boards on the basis of written advice from their appointed external investment advisers and lawyers. There is a consultation process on the SIP with the participating employers as required by law.
The Statements are reviewed by the Trustees annually and also if there are any significant changes to the investment policies.
The Trustees monitor compliance with this statement at least annually. Fund manager activity is reviewed quarterly through reports prepared by investment consultants. Additionally, meetings are held with fund managers at least annually to review the activities and compliance with their contractual terms and with the Statements of Investment Principles.
- GSK Pension Fund SIP
- GSK Pension Scheme SIP
- GW Contracted-out Money Purchase Scheme SIP
- SB Senior Executive Pension Plan SIP
- SB Pension Plan SIP
Socially Responsible Investing
Socially Responsible Investing (SRI) is most commonly understood to mean investing in a manner that takes into account the impact of investments on wider society and the natural environment, both today and in the future. The Trustee of the GSK Pension Plans annually reviews its SRI policies as part of the Trustee business planning process, and the GSK Pension Plans publish ‘Statements of Investment Principles’ which provide a high level overview of the SRI policies.
The Trustee aims to be an engaged and responsible long-term investor in the assets and markets in which it invests. The Trustee believes that the integration of environmental, social and governance (ESG) factors within investment managers’ investment processes is not detrimental to the risk and the sustainable long-term expected returns from pension schemes’ investments.
The Trustee does not wish to interfere with the day to day investment decisions of its investment managers. However, the Trustee does encourage its investment managers to comply with the principles outlined in the UN Principles for Responsible Investment and the UK Stewardship Code where this is appropriate for their mandate, as well as to take into account ESG considerations in the selection, retention and realisation of investments in so far as this is consistent with their overall objectives.
The Trustee regularly reviews the voting strategy of its investment managers. The Trustee also supports the principle of shareholder activism and, for relevant mandates, prefers its investment managers to have an explicit strategy, outlining the circumstances in which they will engage with a company on ESG matters and how they will measure the effectiveness of this strategy.
For GSK Pension Plans, the majority of the assets are managed by Legal and General Investment Management (LGIM). LGIM complies with the principles set out in the UK Stewardship Code and LGIM are also a signatory to the UN Principles for Responsible Investment. In addition, LGIM maintain a large, dedicated team which is responsible for ESG monitoring and which is actively engaged in encouraging companies to improve their ESG standards. A detailed review of LGIM’s ESG activities, including examples of LGIM’s engagement activities with companies, can be found in the “Active Ownership” report below.
A detailed review of LGIM’s ESG activities, including examples of LGIM’s engagement activities with companies, can be found in the “Corporate Governance General Policy”” report below.